# CAIN42 — ARGUS Investor / IP Value Report (Prompt 14)

> **Internal analytical scenario. NOT an appraisal, NOT a financing valuation, NOT a guarantee.** No patent filed;
> pre-revenue; no incorporation record; physical systems SIMULATED. The register method (gross appraisal → blended
> prior-art/deployment discount → net base) is applied consistently with Prompts 6-13.

## Separate the layers (do not conflate)

| Layer | What it is | Today |
|---|---|---|
| Verified technical asset value | code + tests + live evidence, discounted for prior art | see below |
| Development value | the cost to reproduce | not separately claimed here |
| Commercialization value | what customers would pay | **$0 revenue**; no customers |
| Strategic acquisition value | what an acquirer might pay | scenario only |
| Speculative future value | roadmap | not counted |

## Maximum evidence-backed standalone IP base

`scripts/ip/recalculate_ip_value_v14.py` (20 net-new ARGUS families, excluding flagship and prior-prompt overlaps):

| Scenario | Prompt 6-13 base | Prompt 14 gross | Discount | Prompt 14 net | **Total net** |
|---|---|---|---|---|---|
| LOW | $1,105,900 | $498,000 | −55% | $224,100 | **$1,330,000** |
| BASE | $2,587,900 | $1,124,000 | −45% | $618,200 | **$3,206,100** |
| HIGH | $4,756,250 | $1,795,000 | −35% | $1,166,750 | **$5,923,000** |

**BASE (maximum): ≈ $3,206,100** net standalone IP (range ≈ $1,330,000 – $5,923,000).

## Company and founder scenario (premium held at the registered level)

- Investor base scenario: **≈ $4,938,100** (low $2,000,000; high ≈ $8,655,000). Strategic: **≈ $5,938,100**
  (low $3,000,000). Founder Vicente Fernando Noriega (100% owner, **PAPER** equity, not cash): ≈ $4,938,100 (high
  ≈ $8,655,000). No incorporation record exists, so this is not a corporation and not realised net worth.

## What would move the case (evidence, not code)

1. A **paying customer** or paid pilot (the single largest driver).
2. A **third-party security audit / penetration test**.
3. A clean **long-duration soak** of the assurance stages.
4. **Filed patents** (optionality; heavy prior art — not the revenue strategy).
5. **Incorporation with IP assignment** and signed claims registry reconciliation.

Until then, treat every figure above as an internal analytical scenario with a wide range, not a price.
